Published in Medicine and Law Weekly, December 10th, 2004
Under the terms of the amendment, Vitex will issue approximately 54.5 million shares at closing to complete the merger and acquire all Panacos outstanding shares. Panacos shareholders will have the opportunity to receive an additional 30.5 million Vitex shares if it successfully completes Panacos Study 201, a phase 2 study in HIV-infected patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.